Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal … – GlobeNewswire (press release)
|
Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal …
GlobeNewswire (press release) CAMBRIDGE, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today presented … Zacks: Brokerages Expect Intellia Therapeutics, Inc. (NTLA) Will Announce Quarterly Sales of $5.83 Million |
